

### REMARKS

Claims 1-3 have been cancelled by the present application without prejudice or disclaimer as to the subject matter therein. Applicants reserve the right to prosecute this subject matter in a continuing application that claims priority to the present application. Claim 4 has been added and support for this claim can be found on amended page 4, line 3 of the present application.

The specification was objected to under 37 CFR 1.71 because of the lack of correspondence between the sequence identification numbers as listed in the specification and the respective sequence listing. Applicants have amended the specification so that there is now correspondence between the sequence identification numbers in the specification and the respective sequence listing. Specifically, nucleic acid SEQ ID No. 1 and amino acid SEQ ID No. 2 designate *PepThi* and nucleic acid SEQ ID No. 3 and amino acid SEQ ID No. 4 designate *PepDef*. No new matter has been added by these amendments.


Claims 1-3 were rejected under 35 U.S.C. §112, second paragraph. Applicants submit that these rejections are rendered moot by the cancellation of claims 1-3.

Applicants submit that all objections and rejections have hereby been addressed and that the present claims are now in condition for allowance. Any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 11-0600.

Respectfully submitted,

KENYON & KENYON

Date: Jan 16 2004

  
\_\_\_\_\_  
Zeba Ali  
Reg. No. 51,392

1500 K Street, N.W.  
Washington, D.C. 20005  
Telephone: (202) 220-4200  
Facsimile: (202) 220-4201